Plus Therapeutics Inc (PSTV)
$2.25
+0.04
(+1.81%)▲
Insights on Plus Therapeutics Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 1.24M → 1.67M (in $), with an average increase of 13.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -3.81M → -3.26M (in $), with an average increase of 16.8% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 115.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 329.6%
Performance
- $2.16$2.25$2.25
4.22%
Downside
Day's Volatility :4.22%
Upside
0.0%
- $0.97$4.04$2.25
56.92%
Downside
52 Weeks Volatility :76.0%
Upside
44.31%
Returns
| Period | Plus Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 5.63% | 0.0% |
6 Months | 13.64% | 0.0% |
1 Year | -42.31% | 0.0% |
3 Years | -94.49% | -22.6% |
Highlights
Market Capitalization | 12.6M |
Book Value | - $0.3 |
Earnings Per Share (EPS) | -2.92 |
Wall Street Target Price | 28.2 |
Profit Margin | -271.04% |
Operating Margin TTM | -293.98% |
Return On Assets TTM | -47.23% |
Return On Equity TTM | -522.5% |
Revenue TTM | 4.9M |
Revenue Per Share TTM | 1.56 |
Quarterly Revenue Growth YOY | 769.5% |
Gross Profit TTM | -9.5M |
EBITDA | -12.7M |
Diluted Eps TTM | -2.92 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.28 |
EPS Estimate Next Year | -2.65 |
EPS Estimate Current Quarter | -1.09 |
EPS Estimate Next Quarter | -0.75 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1153.33%
Technicals Summary
Sell
Neutral
Buy
Plus Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Plus Therapeutics Inc | 11.94% | 13.64% | -42.31% | -94.49% | -98.24% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Plus Therapeutics Inc | NA | NA | NA | -2.28 | -5.22 | -0.47 | NA | -0.3 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Plus Therapeutics Inc | Buy | $12.6M | -98.24% | NA | -271.04% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
Renaissance Technologies Corp
0.58%Vanguard Group Inc
0.57%Geode Capital Management, LLC
0.51%Ground Swell Capital, LLC
0.25%BlackRock Inc
0.12%Tower Research Capital LLC
0.01%
Company Information
plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.
Organization | Plus Therapeutics Inc |
Employees | 20 |
CEO | Dr. Marc H. Hedrick M.B.A., M.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.25
+1.81%
Keyarch Acquisition Corp
$2.25
+1.81%
Connexa Sports Technologies Inc
$2.25
+1.81%
Us Value Etf
$2.25
+1.81%
First Wave Biopharma Inc
$2.25
+1.81%
Global X Msci Next Emerging
$2.25
+1.81%
Fat Projects Acquisition Corp
$2.25
+1.81%
Goal Acquisitions Corp
$2.25
+1.81%
Capital Link Global Fintech
$2.25
+1.81%